SpectraProject ID: 684584
Financiado con arreglo a:
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
Spectra- A novel diagnostic device to improve retinal imaging
Detalles del proyecto
Coste total:EUR 71 429
Aportación de la UE:EUR 50 000
Coordinado en:United Kingdom
Tema(s):PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices
Convocatoria de propuestas:H2020-SMEINST-1-2015See other projects for this call
Régimen de financiación:SME-1 - SME instrument phase 1
Health Intelligence provide medical software as diagnostic medical devices. We have developed retinal (fundus) photograph analytical software - Spectra, complemented by the lower cost, standalone and portable Spectra Retineye. Spectra is one of only three software packages certified by the English National Diabetic Retinopathy (DR) Screening Programme. It has benefitted screening providers by seamless integration with patient records and ability to monitor over time. Providers reported improved throughput and attendance.
Spectra highlights much more than just DR. In deployments to date, over 50% of urgent eye clinic referrals are for suspected non-diabetic retinopathies. Thus, Spectra detects reliable biomarkers for many conditions. The greatest causes of blindness (after cataracts) are glaucoma, age-related macular degeneration and DR. Spectra can detect early and treatable stages of these diseases, in particular low-pressure glaucoma missed by ocular pressure tests. New markets also exist for diabetic eye screening programmes (DESP) in countries lacking the resources of the UK NHS. Teleopthalmology (enabled by Spectra Retineye) could deliver these.
Both Spectra and Spectra Retineye can deliver economic benefits:
• Reducing need for expensive equipment and highly-qualified staff
• Increased footfall in high-street optometrists from eye screening patients
• Easier and lower cost of screening to patients
• Reduced social security costs due to sight loss
Spectra will deliver tremendous social benefits. Preventable, irreversible sight damage will become rarer, reducing sickness and caring burdens. Spectra Retineye, which is eminently adaptable to teleopthalmology will allow more delivery models. These will detect more problems earlier, including the 46% of diabetics who are unaware they have diabetes and thus risk severe sight loss and other health problems until they are identified.
Aportación de la UE: EUR 50 000
MOSTON ROAD SAXON HOUSE
CW11 3HL SANDBACH